Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786356 | 1.00 | FAAH (0.55) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8326097 | 0.93 | TSHR (0.54) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22525935 | 0.92 | KDM4E (0.64) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22790988 | 0.92 | KDM4E (0.64) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2719632 | 0.92 | FAAH (0.68) | FAAHMEN1KMT2AEPHX1CASP2 | |
| SCHEMBL24029657 | 0.92 | KDM4E (0.64) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22144502 | 0.92 | FAAH (0.49) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22856469 | 0.92 | MEN1 (0.68) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24098140 | 0.92 | FAAH (0.68) | FAAHMEN1KMT2AEPHX1CASP2 | |
| SCHEMBL15888717 | 0.92 | FAAH (0.68) | FAAHMEN1KMT2AEPHX1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | FAAH 2508/4885MEN1 1671/4885KMT2A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.